
FDA Approves Mirvetuximab Soravtansine-Gynx for Treatment of Platinum-Resistant Ovarian Cancer
In exciting treatment news, the Food and Drug Administration (FDA) has granted accelerated approval to mirvetuximab soravtansine-gynx (trade name Elahere, made by Immunogen, Inc.), for adults with folate receptor alpha … Continued